Convertible notes · Biotech
Delix Therapeutics announces more than $30 million in convertible notes
The January 2022 announcement described financing from existing and new investors.
Delix Therapeutics announced on January 10, 2022 that it had closed more than $30 million in convertible-note financing from existing and new investors. It did not name the investors in the notes.
The proceeds supported its neuroplastogen programs, broader pipeline and team. Delix separately announced a $10 million credit-facility option with Comerica Bank.
Use of funds
Advance neuroplastogen development and expand pipeline
Funding history
Convertible notes · This round>$30M
Series A$70M